Surgery Partners (NASDAQ:SGRY) CFO David Doherty Sells 8,867 Shares

Surgery Partners, Inc. (NASDAQ:SGRY) CFO David Doherty sold 8,867 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $12.50, for a total value of $110,837.50. Following the completion of the sale, the chief financial officer directly owned 221,679 shares of the company’s stock, valued at approximately $2,770,987.50. This trade represents a 3.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Surgery Partners Price Performance

SGRY opened at $12.39 on Tuesday. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.87 and a quick ratio of 1.71. The stock’s 50 day simple moving average is $14.89 and its 200 day simple moving average is $17.64. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -19.98 and a beta of 1.95. Surgery Partners, Inc. has a 1 year low of $12.25 and a 1 year high of $24.60.

Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.19). The company had revenue of $885.00 million during the quarter, compared to the consensus estimate of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.44 EPS. As a group, analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.

Surgery Partners declared that its Board of Directors has approved a stock repurchase program on Thursday, February 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 9.7% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on SGRY shares. JPMorgan Chase & Co. dropped their price target on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a research report on Monday, November 24th. UBS Group restated a “buy” rating on shares of Surgery Partners in a research report on Wednesday, March 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Mizuho dropped their target price on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. Finally, US Capital Advisors set a $21.00 target price on Surgery Partners in a research note on Wednesday, March 11th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.36.

More Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Negative Sentiment: CEO Jason Eric Evans sold 20,400 shares at an average price of $12.47 for proceeds of $254,388; he still holds 920,386 shares worth about $11.48M. Form 4 CEO Sale
• Negative Sentiment: CFO David T. Doherty sold 8,867 shares at an average of $12.50 for roughly $110,838; post‑sale ownership is 221,679 shares. Form 4 CFO Sale
• Negative Sentiment: Jennifer Baldock sold 5,798 shares at $13.17 for proceeds of $76,359.66; she retains 326,474 shares. Form 4 Baldock Sale
• Negative Sentiment: Marissa Brittenham sold 3,657 shares at $12.54 for about $45,858.78; post‑sale holdings are 94,196 shares. Form 4 Brittenham Sale
• Negative Sentiment: Danielle Burkhalter sold 3,469 shares at $12.83 for about $44,507.27; she now owns 76,864 shares. Form 4 Burkhalter Sale

Institutional Investors Weigh In On Surgery Partners

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SGRY. Groupe la Francaise grew its position in shares of Surgery Partners by 26.6% in the 2nd quarter. Groupe la Francaise now owns 186,088 shares of the company’s stock worth $4,137,000 after buying an additional 39,089 shares during the period. Irenic Capital Management LP lifted its position in Surgery Partners by 339.7% during the 3rd quarter. Irenic Capital Management LP now owns 1,132,203 shares of the company’s stock valued at $24,501,000 after acquiring an additional 874,704 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. lifted its position in Surgery Partners by 87.9% during the 2nd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 146,250 shares of the company’s stock valued at $3,251,000 after acquiring an additional 68,400 shares during the period. 8 Knots Management LLC bought a new stake in Surgery Partners during the third quarter worth about $4,763,000. Finally, AYAL Capital Advisors Ltd bought a new stake in Surgery Partners during the second quarter worth about $2,779,000.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.